Prognostic and diagnostic validity of p16/Ki-67, HPV E6/E7 mRNA, and HPV DNA in women with ASCUS: a follow-up study

Table 2 Positive rate of HPV DNA assay, HPV E6/E7mRNA testing and p16/Ki-67 immunocytochemistry in CIN1- and CIN2+

Test	positive rate		χ² value	p value
Test	CIN1-	CIN2+	χ² value	p value
DNA	88.7% (86/97)	100% (6/6)	0.037	0.848
E6/E7mRNA	55.7% (54/97)	100% (6/6)	6.749	0.009
p16/Ki-67	17.5% (24/97)	50.0% (3/6)	1.649	0.199

CIN1-: The diagnoses of cytology and HPV DNA negative (no biopsy), cervical inflammation and CIN1 are referred as < CIN1(CIN1 -); CIN2+: the diagnoses of CIN2, CIN3 and carcinoma are referred as ≥ CIN2 (CIN2 +). DNA: HPV DNA assay; E6/E7 mRNA: HPV E6/E7 mRNA testing; p16/Ki-67: p16/Ki-67 immunocytochemistry

ISSN: 1743-422X